<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358602</url>
  </required_header>
  <id_info>
    <org_study_id>TJLC-01</org_study_id>
    <nct_id>NCT03358602</nct_id>
  </id_info>
  <brief_title>Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic Cancer</brief_title>
  <official_title>Radiotherapy Versus Elective Neck Dissection for Management of Cervical Nodes in Clinical T1/2N0 Supraglottic Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supraglottic cancer is a main type of laryngeal carcinoma, which is one of the most common
      head and neck tumors. Cervical nodal metastasis is an important prognostic factor in
      supraglottic cancer. Current management, following the US National Comprehensive Cancer
      Network guidelines for T1-2, N0 supraglottic cancer (NCCN 2017), is either definitive
      radiotherapy or primary surgery with or without neck dissection. The optimal neck treatments
      strategy remains unclear in clinical settings owing to the limitation of a small number of
      retrospective studies and a lack of prospective trials. The investigators conducted a
      prospective, randomised trial to compare radiotherapy with neck dissection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neck control rates</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of patients without cervical lymph node metastasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients did not find clear evidence of recurrence or metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of patients did not find clear evidence of recurrence or metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>The proportion of patients did not find clear evidence of recurrence or metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>The proportion of patients did not find clear evidence of recurrence or metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>The proportion of patients who survived</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>The proportion of patients who survived</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC QLQ-C30)</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluated by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC QLQ-HN35)</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluated by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-HN35</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment cost</measure>
    <time_frame>4 weeks</time_frame>
    <description>The total cost of the treatment of the primary and cervical lymph nodes until the discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Supraglottic Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy &amp; open partial supraglottic laryngectomy(primary tumor)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elective neck dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elective neck dissection &amp; open partial supraglottic laryngectomy(primary tumor)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes</description>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Selective neck dissection</intervention_name>
    <description>Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes</description>
    <arm_group_label>Elective neck dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and the willingness to sign a written informed consent document

          2. Age≥ 18 and≤ 75 years

          3. Histological/ cytological/ Imaging examination proven supraglottic squamous-cell
             carcinoma in preoperative assessment

          4. Cervical node negative according to the imaging characteristics and the physical
             examination

          5. KPS≥ 70

          6. Normal bone marrow reserve function and normal liver, kidney function

          7. Expected survival period≥ 12 months

        Exclusion Criteria:

          1. Inability to provide an informed consent

          2. Proved distant metastasis

          3. Clinical stage 3-4

          4. The patient has received prior surgery or radiotherapy (except for biopsy )

          5. The patient has received chemotherapy(including targeted therapies) or immunotherapy

          6. Prior malignancy within the previous 5 years

          7. Severe mental disorders

          8. Pregnant or lactating women

          9. Other disease requiring simultaneous surgery or radiotherapy

         10. Researchers believe that the situation is unsuitable for participation in the group
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lun Zhang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Xu Wang, Ph.D</last_name>
    <phone>+86 022 23340123</phone>
    <email>wxd.1133@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ze Zhang, MD</last_name>
    <phone>+86 022 23340123</phone>
    <email>zhangze_smu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hopital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Xu Wang, Ph.D</last_name>
      <phone>+86 022 23340123</phone>
      <email>wxd.1133@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ze Zhang, MD</last_name>
      <phone>+86 022 23340123</phone>
      <email>zhangze_smu@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lun Zhang, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>December 10, 2017</last_update_submitted>
  <last_update_submitted_qc>December 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Supraglottic cancer</keyword>
  <keyword>Laryngeal cancer</keyword>
  <keyword>Cervical lymph node</keyword>
  <keyword>Neck dissection</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

